A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A

Thyroid

Volumn 16, Issue 6, 2006, Pages 609-614

  Bae, Sung Jin ^a   Kim, Dae Jung ^b   Kim, Ji Youn ^a   Park, So Young ^c   Choi, Sung Hee ^d   Song, Young Duk ^e   Ki, Chang Seok ^a   Chung, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e National Health Insurance Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; TYROSINE;

ADRENAL TUMOR; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CODON; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; HYPERPARATHYROIDISM; KOREA; ONCOGENE RET; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID GLAND;

ADULT; BASE SEQUENCE; CARCINOMA, MEDULLARY; FAMILY HEALTH; FEMALE; GERM-LINE MUTATION; HUMANS; KOREA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 33745991805     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.609     Document Type: Article

References (26)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BA 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
2. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
3. Gardner E, Papi L, Easton DF, Cummings T, Jackson CE, Kaplan M, Love DR, Mole SE, Moore JK, Mulligan LM 1993 Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 2:241-246.
4. Myers SM, Eng C, Ponder BA, Mulligan LM 1995 Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: A novel C-terminus for RET. Oncogene 11:2039-2045.
5. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M, Raue F1995 Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET Mutation Consortium. J Intern Med 238:343-346.
6. Frank-Raue K, H pner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F 1996 Mutations of the ret protooncogene in German multiple endocrine neoplasia families: Relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783.
7. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Kominoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BA, Mulligan LM 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 276:1575-1579.
8. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB 2003 Multiple endocrine neoplasia type 2: Evaluation of the genotype-phenotype relationship. Arch Surg 138:409-416.
9. Machens A, Niccoli-Sire P, H el J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devox B, Dralle H For the European Multiple Endocrine Neoplasia (EUROMEN) Study Group 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525.
10. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671.
11. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74.
12. Eng C, Smith DP, Mulligan LM, Nagi MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 3:237-241.
13. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis. J Med Genet 37:817-827.
14. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B, The French Calcitonin Tumors Study Group (GETC) 2001 Familial medullary carcinoma with noncysteine RET mutations: Phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86:3746-3753.
15. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Gruendorf M, Raue F, Ritter MM, Höppner W 1998 A new hot spot for mutations in the ret. protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774.
16. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M, Corvol JC, De Keyzer Y, Luton JP, Plouin PF, Bertagna X 1995 The RET protooncogene in sporadic pheochromocytomas: Frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab 80:2063-2068.
17. Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y 1998 Mutational analysis of the RET protooncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet 43:101-106.
18. Harm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH, Chung JH 2001 Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 11:73-80.
19. Koch CA, Huang SC, Vortmeyer AO, Zhuang Z, Chrousos GP, Pacak K 2000 A patient with MEN 2 and multiple mutations of RET in the germline. Exp Clin Endocrinol Diabetes 108;493.
20. Lee MS, Hwang DY, Kim YH, Chung JH, Oh YS, Lee MK, Kim KW 1998 Mutations of RET proto-oncogene in 3 Korean families with MEN2A: Clinical use of new restriction sites for genetic diagnosis. Endocr J 45:555-561.
21. Yang HY, Park YJ, Kwon HJ, Cho KJ, Park JG 1999 Germline mutations of RET gene in a multiple endocrine neoplasia type 2A (MEN2A) family. J Korean Cancer Assoc 31:867-875.
22. Kim HY, Lee JY, Kim SB, Lee KW, Seo JA, Oh JH, Kim SG, Choi KM, Baik SH, Choi DS, Kim NH 2003 A case of multiple endocrine neoplasia 2A with germline mutation of RET gene. J Kor Soc Endocrinol 18:481-488.
23. Chung YJ, Kim HH, Kim HJ, Min YK, Lee MS, Lee MK, Kim KW, Ki CS, Kim JW, Chung JH 2004 RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Thyroid 14:813-818.
24. Asai N, Iwashita T, Murakami H, Takanari H, Ohmori K, Ichihara, M, Takahashi M 1999 Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma. Biochem Biophys Res Commun 255:587-590.
25. Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Althehoefer C, Zerres K, Januszewicz A, Eng C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466.
26. Casanova S, Rosenberg-Bourgin M, Farkas D, Calmettes C, Feingold N, Heshmati HM, Cohen R, Conte-Devolx B, Guillausseau PJ, Houdent C, Bigorgne JC, Boiteau V, Caron J, Modigliani E 1993 Phaeochromocytoma in multiple endocrine neoplasia type 2 A: Survey of 100 cases. Clin Endocrinol (Oxf) 38:531-537.